The B case describes the events – including the offers and the negotiation – leading up to Sundown’s acquisition of Cyna for US$40.50 per share in cash or US$624 million (approximately C$841 million) – a 120% premium over the closing price of just over US$18 a share before the deal was announced. The case also brings the reader up to date on the turns Anthony’s life has taken since the acquisition and some of the exciting ventures in which he is now involved.
- Managing growth in a biopharma company
- Leadership in a pharma company, from start-up to listed firm and trade sale
- Developing resilience in a firm – managing risk
Cyna Pharma (Disguised), Health Care, Biopharmaceuticals
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications